Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target hoisted by investment analysts at Wells Fargo & Company from $1.00 to $3.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective suggests a potential downside of 3.54% from the company’s current price.

IRWD has been the subject of several other reports. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.34.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $3.11 on Tuesday. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.13. The firm has a market capitalization of $505.17 million, a PE ratio of -62.19 and a beta of 0.37. The company has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $1.08.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Armistice Capital LLC grew its holdings in shares of Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock valued at $20,139,000 after buying an additional 4,232,000 shares during the last quarter. Millennium Management LLC lifted its position in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after acquiring an additional 4,140,439 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Ironwood Pharmaceuticals by 147.6% during the 2nd quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock valued at $4,685,000 after purchasing an additional 3,904,498 shares during the last quarter. AQR Capital Management LLC boosted its stake in Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after purchasing an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Ironwood Pharmaceuticals by 616.3% in the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 3,436,036 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.